title: Carbapenemase-producing enterobacteriaceae in Spain in 2012.
abstract: We report the epidemiological impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2012. Of the 237 carbapenemases detected, 163 were from the OXA-48 group, 60 were from VIM-1, 8 were from KPC-2, 5 were from IMP, and 1 was from NDM-1. Interhospital spread of carbapenemase-producing Klebsiella pneumoniae was due to a limited number of multilocus sequence types (MLST) and carbapenemase types, including ST15-VIM-1, ST11-OXA-48, ST405-OXA-48, ST101-KPC-2, and ST11-VIM-1. The number of CPE cases in Spain has increased sharply in recent years, due mainly to the emergence of OXA-48.
authors.affiliation: Antibiotic Laboratory, Bacteriology Department, Centro Nacional de Microbiología, Majadahonda, Madrid, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Oteo
authors.forename: David
authors.initials: D
authors.lastname: Saez
authors.forename: Verónica
authors.initials: V
authors.lastname: Bautista
authors.forename: Sara
authors.initials: S
authors.lastname: Fernández-Romero
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Hernández-Molina
authors.forename: María
authors.initials: M
authors.lastname: Pérez-Vázquez
authors.forename: Belén
authors.initials: B
authors.lastname: Aracil
authors.forename: José
authors.initials: J
authors.lastname: Campos
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests; D058885:Multilocus Sequence Typing; D013030:Spain; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001618:beta-Lactamases; C063912:carbapenemase
references.citation: Clin Infect Dis. 2007 Nov 1;45(9):1171-8
references.pmid: 17918078
references.citation: J Antimicrob Chemother. 2010 Dec;65(12):2695-7
references.pmid: 20851814
references.citation: Int J Antimicrob Agents. 2012 Feb;39(2):168-72
references.pmid: 22115539
references.citation: Antimicrob Agents Chemother. 2005 Aug;49(8):3492-4
references.pmid: 16048967
references.citation: J Med Microbiol. 2012 Jun;61(Pt 6):864-867
references.pmid: 22383442
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4793-9
references.pmid: 15561858
references.citation: Trends Mol Med. 2012 May;18(5):263-72
references.pmid: 22480775
references.citation: Euro Surveill. 2013 May 30;18(22):
references.pmid: 23787077
references.citation: J Antimicrob Chemother. 2013 Feb;68(2):317-21
references.pmid: 23034714
references.citation: Clin Microbiol Infect. 2012 May;18(5):413-31
references.pmid: 22507109
references.citation: Eur J Clin Microbiol Infect Dis. 2013 Feb;32(2):253-9
references.pmid: 22956023
references.citation: J Antimicrob Chemother. 2013 Jan;68(1):89-96
references.pmid: 23045224
references.citation: Pediatr Infect Dis J. 2010 Dec;29(12):1144-6
references.pmid: 20686438
references.citation: Clin Microbiol Rev. 2012 Oct;25(4):682-707
references.pmid: 23034326
references.citation: Antimicrob Agents Chemother. 2012 Jan;56(1):420-7
references.pmid: 22005997
references.citation: FEMS Microbiol Rev. 2011 Sep;35(5):736-55
references.pmid: 21303394